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ABSTRACT
Objective: The objective of this study was to 
prepare and evaluate a matrix type transdermal patch of 
ropinirole using blends of 
hydroxypropylmethylcellulose (HPMC) and Eudragit 
RL 100 and HPMC and Eudragit ERS100. Materials 
and Methods: Ropinirole free based used as the drug 
entity was prepared from its hydrochloride salt. 
Suitability of the polymers in the form of drug-excipient 
compatability was determined prior to formulation 
development using FTIR. Patches were developed using 
solvent evaporation technique. Limonene was used as 
a penetration enhancer. Moisture absorption,
moisture content and mechanical properties, drug 
content, in vitro drug release, drug-excipient compatibility, 
in vitro skin permeation were the in vitro parameters 
measured. Short-term stability, skin irritation and 
in vivo drug release were measured with one 
optimized formulation. Results and discussion: 
Ropinirole free base was used successfully in the 
preparation of the patches. FTIR studies indicated no 
interaction between the drug and the polymers of this 
study. Formulations developed were strong and not 
brittle with uniform drug release. Patches containing 
higher HPMC generally showed higher drug release
and permeation. Drug release and permeation decreased 
with increase in the concentrations of Eudragits. Drug 
release studies indicated Higuchi model for all the 
patches with a diffusion mechanism of non-fickian type.
Short-term stability studies indicated that ropinirole
was stable in the patches. Patches did not cause any skin 
irritation. In vivo the optimized patch sustained drug 
release for 24 hours upon one time administration.
Conclusion: Clinically viable ropinirole transdermal 
patch can be successfully prepared from its base form 
using HPMC/Eudragits. 
Keywords: Drug release, QbD, Permeation, Parkinsonism, 
Permeation enhancer
INTRODUCTION
Despite the popularity of oral delivery 
approaches, alternatives with added advantages such as 
drug loaded skin patches are shooting up in important 
healthcare product category (1-3). Skin patches offer the 
advantages of ease of use, painlessness, disposability, 
control of drug delivery and avoidance of first-pass 
metabolism by the liver (4,5). Advances in synthetic 
materials and patch design have led to patches that are 
more esthetically acceptable and that are capable of 
delivering sustained dosing of active compounds for 
several days in a smaller package. Patches relying on 
passive transport mechanisms have been limited in their 
ability to deliver new classes of drugs, but formulations 
employing penetration enhancers, and patch designs 
incorporating microporation and energy assisted delivery 
are expanding the range of drugs that can be effectively 
delivered transdermally. As of today, the simple passive 
transdermal patches are the state of art technology. In this 
paper, we describe the development of a patch for 
ropinirole, a drug approved for the treatment of 
Parkinsons disease (PD) and Restless Legs Syndrome 
(RLS).
Ropinirole (4-(2-di-n-proylaminoethyl)-2)3H)-
indolone) is drug of choice for the treatment of Parkinsons 
Disease (PD). Sustain release has added advantages for the 
therapeutic use of this drug (6-9). Transdermal delivery 
system is one such sustained release dosage form. 
Transdermal patches not only offer better patient 
compliance but also in terms of safety profile, they offered 
better profile than oral SR formulations in Parkinsonism
(10). Thus, a skin patch for ropinirole is desirable. Also, 
ropinirole is pharmaceutically suitable for the development 
of a transdermal patch (11). The compound has a M.Wt of 
296.84 and melting point of approximately 2470C. The 
oral bioavailability of ropinirole was about 50% due to first 
pass metabolism. In addition, it has low dose, low 
molecular weight and octanol/water partition co-efficient 
of 2.3. Transdermal patch for rotigotine, another drug for 
PD has been approved for clinical use and is successful in 
the market. On the other hand, skin penetration of 
ropinirole HCl salt, which is the form of the drug that is 
clinically used, is very low and it is not practical to achieve 
clinical drug levels with this salt form (12). Although 
penetration enhancers successfully enhanced its skin 
permeation, clinical levels are not observed with the salt 
form of ropinirole (13). Preliminary results from our 
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laboratory corroborated this observation. Previously, one 
report indicated that transdermal formulations were able 
to provide a therapeutically useful amount of the drug 
when administered in the form of free base (14). The 
device proposed in this patent is complicated as well it is a 
reservoir type of transdermal patch. In this study, we 
aimed at the development of a simple clinically vaiable 
transdermal patch for ropinirole. The present study was 
designed to develop a suitable matrix patch type TDDS 
for ropinirole (as free base) employing various blends of 
HPMC and Eudragit RL100 and HPMC and Eudragit 
ERS 100.  Polymer blending which results in new material 
is one of the effective ways of developing a better 
pharmaceutical device at a cheaper cost when compared to 
the development of newer polymers. The aim was to 
compare the polymeric combinations in terms of in vitro
skin permeation of the drug. Thus, an attempt was made 
to establish the best possible combination of polymeric 
ratio that ensures maximum controlled and sustained drug 
release with good physical properties to the patch. This 
will determine the drug delivery at a controlled rate across 
intact skin to achieve a therapeutically effective drug level 
for a longer period of time and also gives  ideal 
characteristics to the patch. Further the influence of d-
Limonene, a penetration enhancer on the skin permeability 
of this drug was also evaluated. Penetration enhancers are 
widely used in the transdermal drug delivery systems 
(15,16). A best transdermal patch was selected and further 
in vivo studies were conducted to determine the 
sustenance of systemic drug release and skin irration, 
short-term stability studies were also conducted. 
METHODS
Materials
Ropinirole. HCl was gift sample from Hetero Drugs 
Ltd., Andhra Pradesh, India. Limonene was procured 
from Himedia Laboratories Pvt. Ltd., Mumbai. Eudragit
RL 100(ERL 100), Eudragit RS 100(ERS 100) and  
Hydroxy propyl Methyl Cellulose (HPMC) were gift
samples from Degussa, Germany. All other chemicals used
were of analytical grade. 
Synthesis of Ropinirole Free Base
Prior to the preparation of the matrices, the 
ropinirole free base was synthesized from its 
hydrochloride salt using a slight modification of a 
previously published method (17). Briefly, ropinirole 
hydrochloride (1.9 g), water (13.5 mL) and ammonia (1.6 
mL) were added to a flask with a stirrer. The reaction 
mixture was stirred at room temperature for 
approximately 2 hours and then extracted continuously 
with dichloromethane (1X500 mL, 1X250 mL and 1X200 
mL). All the organic extracts were combined and then 
evaporated to obtain a light brown solid. The yield of the 
base was determined and then it was characterized using 
NMR.
Permeation Studies to Identify the Suitable Molecular 
Entity and also to Determine the Role of Limonene as 
the Penetration Enhancer
To identify the suitable molecular entity, permeation 
studies across rat skin with ropinirole. HCl and ropinirole 
free base were performed. Male albino rats were used in 
this study. All the animal experiments were conducted 
according to the rules and guidelines of Committee for the 
Purpose of Control and Supervision of Experiments on 
Animals (CPCSEA, Chennai) constituted by the 
Government of India. The protocol was approved by 
Institutional Ethical Committee of Vaagdevi College of 
Pharmacy, Ramnagar, Warangal, India. The rats
weighing 150-200 gm were sacrificed using anesthetic
ether. The hair of test animals were carefully trimmed
short (<2 mm) with a trimmer taking extreme precaution 
not to damage the skin and the full thickness skin was
removed from the abdominal region. The epidermis was
prepared surgically by heat separation technique, which 
involved soaking the entire abdominal skin in water
at 60oC for 45 sec, followed by careful removal of the 
epidermis (18). The epidermis thus obtained was 
immediately used in the study. 
Franz diffusion cell with a surface area of 4.15 cm2
was used f o r ex vivo permeation studies. The rat  skin 
was mounted between the compartments of the
diffusion cell with stratum corneum facing the donor
compartment (19). The stratum corneum side of the skin
was kept in intimate contact with the release surface of
the drug. The relative potential of ropinirole (as the free 
base) and a ropinirole salt for formulation for incorporation 
into transdermal delivery system was evaluated from 
suspensions or solutions of drug. Either saturated solutions 
of ropinirole hydrochloride or ropinirole free base 
suspension were used to study the permeability. The 
receiver phase is 24 mL of phosphate buffer saline
(PBS) pH 7.4 stirred at 500 rpm on a magnetic stirrer. 
The amount of drug permeated was determined by
removing  5 mL of sample at appropriate time intervals
upto 24 h, the volume was replenished with an equal
volume of PBS pH 7.4.The absorbance was measured at
250 nm spectrophotometrically. Cumulative amount of
drug permeated in µg/cm2  were calculated and plotted
against time. Drug flux (µg/hr/cm
2) at steady state was
calculated by dividing the slope of the linear portion of
the curve by the area of the exposed skin surface (4.15
cm2) and the permeability coefficient was deduced by
dividing the flux by initial drug load as shown in Table
2. L imonene was  investigated as  a  penetration 
enhancer .  The permeab i l i ty  of  both the  sa lt  form 
and free  base  were  s tudied in  the  presence  o f  
increasing concentrations o f  l imonene . 
Limonene concentrations  from 0  to  12% of the 
act ive were tested as  penetration  enhancer
Development of Transdermal Films
Based on the permeability results, ropinirole free 
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base was selected as the final drug form. To study the
possible interaction between ropinirole and polymeric
materials of the films, infrared (IR) spectroscopy was
carried out on pure substances and their physical   
mixtures.  The  IR   spectra  were  recorded  using  IR-
Spectrophotometer (Perkin Elmer FT-IR, Perkin Elmer
Inst. USA) by KBr pellet method. After confirmation that 
there was no interaction with the polymers proposed and 
the drug, the patches were prepared. Matrix type
transdermal patches containing ropinirole free base were
prepared by solvent evaporation technique, using
different ratios of ERL 100 (or ERS 100) and HPMC E
15 (Table 1). The polymers were weighed in requisite
ratios by keeping the total polymer weight 2gm and
allowed for swelling for about 6 hrs in solvent mixture
(1:1 ratio of di-chloromethane, methanol).15%v/w 
Propylene glycol was incorporated as plasticizer and 
8 %v/ w l i monene as penetration enhancer (optimum 
concentration determined). Then the drug solution was
added to the polymeric solution, casted on to anumbra 
Petri plate of surface area about 72.3 sq.cm, allowed for
air drying over night. The entire sheet was cut into small 
films with an area of 4.15 cm2 i.e. with a diameter of 2.3
cm. About 10 films were obtained from each sheet. The 
dry patches were kept in desiccators until use. 
Physical Characteristics of the Prepared Films
The following studies were conducted:
Moisture Absorption Study
The films were weighed accurately and placed in
a desiccator containing 100 ml of saturated solution of
aluminum chloride (79.50% RH). After 3 days, the films
were taken out and weighed, the percentage of moisture
uptake was calculated using formula.
% moisture absorbtion=                                      X100  ….(1)         
                                                         
Moisture Content
The films were weighed and kept in a desiccator
containing calcium chloride at 40oC for 24 h. The final
weight was noted when there was no further change in
the weight of patch. The percentage of moisture content
was calculated as a difference between initial and final
weight with respect to initial weight.
Measurement of Mechanical Properties
Mechanical properties of the films were
evaluated using a microprocessor based advanced force
gauze (Ultra Test, Mecmesin, UK) equipped with a 25
kg load cell. Film strip with dimensions 60 x 10 mm
and free from air bubbles or physical imperfections were
held between two clamps positioned at a distance of 3
cm. During measurement, the top clamp at a rate of 2
mm/s pulled the strips to a distance till the film broke. 
The force and elongation were measured when the film
broke. The mechanical properties were calculated 
according to the  following formulae (20).  
Measurements were run in four replicates for each
formulation.
Tensile strength (kg. mm–2) =                                          ..(2)
                                                  Initial cross sectional area
                                                   of the sample (mm2)
Elongation at break (%.mm–2) =Increase in length (mm) / 
original length X 100/cross sectional area………….(3)
Elastic module= Force at corresponding strain (kg)/ Cross-
sectional area (mm2) X 1/ Corresponding Strain ……….(4)   
Strain  =Tensilestrength/Elastic modulus……………(5)
                                    
Determination of Drug Content in the Patches and In
vitro Release Mechanisms
To determine drug content, an in vitro dissolution 
study was conducted using USP dissolution apparatus in 1 
L of dissolution media (phosphate buffered saline) keeping 1 
cm2 of patch cut in several pieces. Aliquot samples were 
taken from the dissolution media at different time intervals 
until spectrophotometer readings became constant for 
atleast 24 h
. The cumulative amount of the drug released was 
considered to be the amount of the drug content in the 
patch. The samples were analyzed spectrophotometrically 
at 250 nm (21,22) and the amounts of drug present were 
calculated from the calibration curve.  
The drug release studies from ropinirole
transdermal films were performed using Franz Diffusion 
cell. The drug containing film was kept between donor and 
receiver compartments, separated from these compartments 
by dialysis membrane of molecular weight cut off of 5000 
(Himedia, Mumbai, India) (23). The receiver compartment 
containing diffusion medium was stirred with magnetic 
bead operated by magnetic stirrer, to prevent the formation 
of concentrated drug solution layer below the dialysis 
membrane. Normal saline containing 20% v/v of 
polyethylene glycol 400 was used in the receiver. In the 
study of release of drug from patches, the selection criteria 
of the receiver compartment is important (24). Biphasic 
characteristics of the receiver compartment fluid is 
important as the diffusion of the drug is through both 
aqueous and non-aqueous heterogenous media. PEG 400 
and normal saline are commonly chosen to provide the 
biphasic characteristic of the receiver fluid. Additionally, 
PEG 400 is a non-interacting fluid in the receiver 
compartment (25). 5 mL of sample was collected from the 
receptor compartment at appropriate time intervals and 
replaced with phosphate buffer pH 7.4. Analysis was carried 
out using UV-Vis Spectrophotometer at 250 nm against
phosphate buffer pH 7.4 as reference. Mathematical 
expressions, zero order , First order and Higuchi 
               Final weight-Initial weight
Initial weight
Force at break (kg)                              
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model   were applied to analyze the release mechanism
from the transdermal films.
Ex Vivo Skin Permeation
Ex vivo skin permeation studies were conducted to 
determine the optimum formulation that can be clinically 
used. The experimental set up is same as that used for skin 
permeation studies with the drug but instead of the drug 
solution or suspension, a transdermal patch was clamped 
between the donor and the receiver compartment. In case 
of transdermal patches, a dialysis membrane was a l s o  
placed over the skin, so as to secure the patch tightly
dislodged from the skin. The receiver compartment 
also consisted of the same media used in the drug 
release studies for the same reason. 
The target flux was calculated using the following
equation (11).
  JTarget=CssCLTBW/A…………………(6)
         ‘A’ represents the surface area of the transdermal
patch (i.e. 4.15 cm
2), ‘BW’ the standard human body
weight of 60 kg, ‘Css’ the ropinirole concentration at
the therapeutic level (18ng/mL) and the ‘CLT’ the
total clearance (13.05 mL/min/kg), the calculated target
flux value for ropinirole was 3.396 µg/h/cm2.
In Vivo Studies
Primary Skin Irritation Test
The dorsal part of the rats was carefully 
shaved and the patch was applied on the shaved 
portion for 7 days. After 7 days, the patch was 
removed and the skin irritation was evaluated as per 
Draize et al. (1944) (26). Briefly, scores are given 
from 0 to 4 based on the severity of erythema or 
oedema formation. The safety of the patch decreases 
with increase in score. 
In Vivo Drug Release
The rats were divided into three groups, one 
control group, the second group received the patch
and the third group received the drug via oral route. 
In vivo drug release was determined in rats. After 
carefully shaving the abdomen portion of the rat, the 
patch containing 9 mg ropinirole was placed on the 
skin of the rat (patch A1 which exhibited the highest 
cumulative amount was selected as optimized 
formulation and was used in the in vivo studies). 
Ropinirole. HCl (9 mg) via the oral route was given 
to the rats to confirm the pharmacological activity 
and assesses the activity with the patch. Anxiolytic 
activity of ropinirole was used as the criteria for the 
assessment of systemic drug release (27,28). Light 
and dark arena, a non-conflicting animal 
experimental model for anxiety was used for testing 
the anxiolytic activity of the released drug. The 
apparatus is described in detail else where (28). 
Briefly, each rat was placed in the center of the light 
arena of the apparatus and was allowed to explore it 
for 5 min. Percentage of time spent in light arena was 
observed during specific time points after the drug 
administration till the next 24 hours. 
Short-term Stability Studies
The optimized patch was subjected to short term 
stability studies. The patches were packed in the 
aluminum foil and kept at 40±2ºC and 75 ±5% RH. At the 
end of one month of storage, the patches were removed 
and assayed for drug content using a UV-Vis 
spectrophotometer. To determine the drug levels, the 
same method used for drug content determination was 
followed. The degradation of ropinirole was evaluated 
using a TLC method. 
Statistical Analysis
The data were analyzed using GraphPad InState 
Demo (version 3.10) and Microsoft Excel 2007. The 
release data and permeation parameters obtained were 
compared by one-way analysis of variance (ANOVA). 
Tukey-Kramer test and Dunnett test were performed for 
multiple comparisons amongst the different formulations, 
respectively. The probability level, p < 0.001, was 
considered statistically significant.
RESULTS AND DISCUSSION
        Ropinirole was successfully synthesized from 
ropinirole.HCl. At the end of the synthesis, a light brown 
solid with 75% yield was obtained. The structure was 
confirmed using NMR. NMR [5H(CDCl3 )] yielded the 
following: 0.9 (6H,t), 1.5(4H,m), 2.7(3H,s)3.5(2H,s)6.7-6.9 
(3H,m,Ar),8.6(2H,br,NH). From the ex vivo studies using 
the free base and the salt, it was found that the penetration 
of the free base is 20 fold higher than the salt from 0.9% 
saline vehicle. As a reason, the skin patches were developed 
using the free base along with the incorporation of suitable 
concentration of limonene as penetration enhancer. From 
the permeability studies, for both the base and the salt, 8% 
of limonene was optimum concentration as a penetration 
enhancer. Thus, this concentration was incorporated into 
the patches. Drug-excipient interaction was studied prior to 
the fabrication. The aim to study drug-polymer interaction
in this manner was to develop the formulation by a QbD 
approach. Pharmaceutical quality by design (QbD) is a 
systematic, scientifically based, holistic and proactive 
approach to pharmaceutical development, where selection of 
excipients followed by the study of their mutual 
compatibility is the first step in the formulation 
development (29).  In FTIR, all the principal peaks shown 
with ropinirole appeared in the ropinirole patch suggesting 
no chemical interaction between the drug and the polymers
selected. As a reason, transdermal patches were prepared 
using these polymers. Ten different patches with series A 
(from A1 to A5) and series B (from B1 to B5) were 
successfully prepared using the solvent evaporation method 
by taking the base prepared from the above step (Table 1). 
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Table 1. Composition of different transdermal ropinirole films 15%v/w propylene glycol was used as plasticizer.
8% v/w limonene was used as penetration enhancer in all formulations.
Each patch (4.15cm2) contains 9mg of Ropinirole.
The physicochemical studies like moisture 
content, moisture uptake and mechanical properties   etc. 
provide information regarding the stability of TDDS 
formulations. The results of moisture content and
moisture absorption studies are shown in Fig. (1). The
moisture content in the films ranged from 1.8±0.81 to
4.5±0.96% and 2.6±1.90 to 4.6±1.50% (for formulation A
series and formulation B series respectively). The
moisture absorption in the formulations is ranged from
3.4±0.96 to 18±1.74% and 2.8±1.12 to 15.1±1.75% (for
formulation A series and formulation B series
respectively). The results revealed that the moisture
absorption and moisture content was found to increase
with increasing ratio o f hydrophilic polymer (HPMC). The
small moisture content in the formulations helps them to
remain stable and from being a completely dried and
brittle film. The tensile testing gives an indication of the
strength and elasticity of the film, reflected by the 
parameters, tensile strength (TS)  and elastic modulus
(EM)  and elongation at break (E/B). Another parameter
strain has been used as an indicator of the overall
mechanical quality of the film. A suitable transdermal film
should have a relatively high TS, E/B and strain but low
EM. The results of mechanical properties (tensile
strength, elongation at break, elastic modulus and strain)
are shown in Table 2. Formulation A1 and B1 exhibited
greater values of tensile strength and elastic modulus
(2.01±0.308 kg/mm2 and 4.96±0.0.609 kg/mm2 for  A1;
1.88±0.221 kg/mm2 4.89±0.616 kg/mm
2 
respectively).
The results revealed that as the ratio of HPMC
increased, the tensile strength and elastic modulus were
found to be increased but elongation at break values
decreased. An inverse relation was observed between 
tensile strength and elongation at break. These 
observations indicate that formulation A1 and B1 
films were found to be strong, not brittle and flexible.
In vitro dissolution studies were carried out for the 
different formulations using USP dissolution apparatus to 
determine the drug content in the patches. The patches had 
uniform drug amounts present with the drug amounts in 
all the patches. An average of 9 mg of the drug was present 
in each patch. Very low standard deviation between and 
within patches indicated homogenous distribution of the 
drug in the patches, suggesting that the technique of 
preparation was good.  Figures. (2) And (3) show the
release profiles of ropinirole from transdermal films.
Formulations A1 and B1 exhibited greatest (89.92±6.002
and 87.54±2.58 % respectively) percentage of drug release 
values,  which  are significantly different compared to
the lowest values observed with the formulations
containing ERL 100 and ERS 100 (60.49 ±7.77 and
57.29 ±2.84 % respectively). In the present study it was
observed that as the ratio of hydrophilic polymer
(HPMC) increased in the formulations, the d r u g
r e l e a s e r a t e   increased s u b s t a n t i a l l y .  The
description of dissolution profiles by a model function
has been attempted using d i f f e r e n t kinetics (zero
order, first order and Higuchi square-root model). 
Higuchi square route seemed to be the most appropriate
model describing kinetics from all f i lms (correlation 
coef f i c i ent between 0.901 and 0.998). On the other
hand n values (0.721 ≤ n ≥1.012) indicated that amount 
of released drug was by non Fickian diffusion (30).
   The results of in vitro skin permeation of ropinirole
from films are shown in Figures. (4) and (5). The
formulations (area of 4.15cm2) A1 and B1 exhibited
the greatest  (1603.11 ±28.63 and 1507.45±59.54 µg/cm2
respectively) cumulative amount of drug permeation,
which were significantly different compared to the 
lowest values observed with the formulations containing
ERL 100 (Formulation A5) and ERS 100 (Formulation
B5) (307.90 ± 16.81 and 237.50± 10.02 µg/cm2
respectively) in 24 hr. The permeation profiles of drug




A1 A2 A3 A4 A5 B1 B2 B3 B4 B5
Ropinirole(mg) 200 200 200 200 200 200 200 200 200 200
HPMC E15(mg) 1600 1200 800 400 -- 1600 1200 800 400 --
Eudragit RL100(mg) 400 800 1200 1600 2000 -- -- -- -- --
Eudragit RS100(mg) -- -- -- -- -- 400 800 1200 1600 2000
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by correlation coefficients (0.918 to 0.986) better than
first order (r2   = 0.646 to 0.798) and Higuchi’s
Table 2.Tensile Strength, Elongation at Break, Elastic Modulus and Strain values of   Ropinirole Transdermal Films
Values represent mean ± SD (n=3).
Formulation Tensile Strength
(kg/mm2)





A1 2.01± 0.308 62.02 ± 2.098 4.96 ± 0.609 0.63 ± 0.021
A2 1.52±0.226 77.92 ± 3.076 3.25 ± 0.446 0.52 ± 0.018
A3 1.23 ±0.251 80.70 ± 3.869 2.54 ± 0.401 0.69 ± 0.024
A4 0.48± 0.052 81.63 ± 4.918 0.98 ± 0.107 0.46 ± 0.016
A5 0.29 ±0.047 91.19 ± 5.862 0.53 ± 0.109 0.40 ± 0.014
B1 1.88 ± 0.221 64.86 ± 3.208 4.89 ± 0.616 0.31 ± 0.011
B2 1.46± 0.186 71.16 ± 4.633 3.42 ± 0.402 0.61 ± 0.021
B3 0.98±0.068 78.14 ± 3.986 2.09 ± 0.312 0.34 ± 0.012
B4 0.44± 0.051 86.07 ± 4.587 0.85 ± 0.410 0.46 ± 0.016
B5 0.17± 0.028 91.39 ± 5.578 0.31 ± 0.098 0.51 ± 0.018
equation (r2  = 0.915 to 0.961). As the proportion HPMC 
increased in all the formulations, increased drug release and 
permeation in both series were observed. The required flux 
was obtained with formulation A1 (3.52 µg/cm2/hr) and B1 
(3.41 µg/cm2/hr) (Table 3).
Because of these values as well as mechanical properties, the 
patches A1 and B1 were selected as optimum formulations 
with desired flux. Of these two A1 was selected as the best 
formulation. This formulation was investigated for in vivo
drug release. As the concentration in the plasma that is 
anticipated to be attained with ropinirole transdermal patch 
is very low and requires a sophisticated analytical 
technique, instead, we used one of its pharmacological 
activity to assess its systemic presence. significant 
anxiolytic activity (27). We observed similar results after 
administering 9 mg of the drug orally. Peak activity was 
shown at the end of 1 hour (Figure 6). With the 
transdermal patch anxiolytic activity was shown for upto 24 
hours demonstrating the usefulness of the patch in attaining 
systemic levels of the drug. The primary skin irritation 
studies revealed that the patch caused any noticeable 
irritation on the rat skin. The stability studies indicated that 
the drug is stable in the short-term stability studies. TLC 
studies confirmed that there is no degradation product at 
the end of one month and as a reason a UV-Vis 
spectrometer can be conveniently used to determine the 
stability data. Thus, this study successfully developed a 
transdermal patch for ropinirole using its base form.  
Further elaborate studies on the formulation development 
and clinical studies have to be performed to bring this 
formulation into market reality.
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Table 3. :In vitro Drug Release, Ex vivo Skin Permeation, Transdermal Flux and Permeability Coefficient of Ropinirole
Transdermal Films
Fig.1: Moisture absorption and moisture content of Ropinirole transdermal films,










A1 89.92±6.002 1603.07±28.95 3.52±0.81 0.137±0.089
A2 86.58±6.053 1244.93±27.78 2.85±0.56 0.114±0.076
A3 81.55±9.45 949.28±26.12 2.52±0.38 0.103±0.065
A4 71.44±6.21 753.53±35.38 1.85±0.49 0.075±0.043
A5 60.49±9.77 381.48±52.67 1.63±0.62 0.066±0.048
B1 87.54±2.58 1507±59.95 3.41±0.65 0.136±0.079
B2 82.64±4.6 1137.43±85.74 2.75±0.29 0.111±0.086
B3 76.79±5.05 881.79±93.38 2.62±0.18 0.107±0.067
B4 68.94±5.07 677.08±79.13 1.62±0.52 0.067±0.042
B5 57.29±2.84 414.41±42.75 1.38±0.38 0.054±0.026
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Fig. 2: Release of ropinirole from Transdermal films(A series),mean ± SD (n=3)
    Fig. 4: Permeation of Ropinirole from transdermal films (A Series) through rat abdominal skin, mean ± S.D (n=3)
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Fig. 5: Permeation of Ropinirole from transdermal films (B Series) through rat abdominal skin, mean ± S.D (n=3)
CONCLUSION
Matrix  type  transdermal  therapeutic  systems  of 
ropinirole could be prepared with the required flux having 
suitable mechanical properties. Further work is 
recommended in support of  its  efficacy  claims  by  long  
term  pharmacokinetic  and pharmacodynamic studies on 
human beings.
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